Literature DB >> 11704999

Initial treatment of differentiated thyroid carcinoma.

B R Haugen1.   

Abstract

Many large, retrospective studies have been performed and form the basis for how we define risk groups of patients with differentiated thyroid carcinoma and how the three basic therapeutic modalities (surgery, radioiodine and levothyroxine) affect two primary outcomes disease recurrence and death. In this review, we have hopefully distilled much of that information into a proposed current therapeutic approach to individual patients with differentiated thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11704999     DOI: 10.1023/a:1010066728437

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  37 in total

1.  PAPILLARY CARCINOMA OF THE THYROID. A CLINICAL AND PATHOLOGICAL STUDY OF 70 FATAL CASES.

Authors:  H R TOLLEFSEN; J J DECOSSE; R V HUTTER
Journal:  Cancer       Date:  1964-08       Impact factor: 6.860

2.  Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer.

Authors:  L A Burmeister; M O Goumaz; C N Mariash; J H Oppenheimer
Journal:  J Clin Endocrinol Metab       Date:  1992-08       Impact factor: 5.958

Review 3.  A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example.

Authors:  J D Brierley; T Panzarella; R W Tsang; M K Gospodarowicz; B O'Sullivan
Journal:  Cancer       Date:  1997-06-15       Impact factor: 6.860

4.  Adequacy of TSH suppression by L-thyroxine administration in thyroid cancer patients after total thyroidectomy.

Authors:  A Pinchera; E Martino; L Bartalena; A Pacchiarotti; F Aghini-Lombardi; L Grasso
Journal:  J Endocrinol Invest       Date:  1986       Impact factor: 4.256

5.  The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.

Authors:  R W Tsang; J D Brierley; W J Simpson; T Panzarella; M K Gospodarowicz; S B Sutcliffe
Journal:  Cancer       Date:  1998-01-15       Impact factor: 6.860

6.  Trends in treatment and long-term survival of thyroid cancer in southeastern Netherlands, 1960-1992.

Authors:  J L Kuijpens; B Hansen; J F Hamming; J G Ribot; H R Haak; J W Coebergh
Journal:  Eur J Cancer       Date:  1998-07       Impact factor: 9.162

7.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

8.  Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases.

Authors:  N A Samaan; Y K Maheshwari; S Nader; C S Hill; P N Schultz; T P Haynie; R C Hickey; R L Clark; H Goepfert; M L Ibanez; C E Litton
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

9.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients.

Authors:  N A Samaan; P N Schultz; R C Hickey; H Goepfert; T P Haynie; D A Johnston; N G Ordonez
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

10.  Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.

Authors:  D S Cooper; B Specker; M Ho; M Sperling; P W Ladenson; D S Ross; K B Ain; S T Bigos; J D Brierley; B R Haugen; I Klein; J Robbins; S I Sherman; T Taylor; H R Maxon
Journal:  Thyroid       Date:  1998-09       Impact factor: 6.568

View more
  4 in total

Review 1.  Overview of the management of differentiated thyroid cancer.

Authors:  Jyotika K Fernandes; Terry A Day; Mary S Richardson; Anand K Sharma
Journal:  Curr Treat Options Oncol       Date:  2005-01

2.  Expanding indications for recombinant human TSH in thyroid cancer.

Authors:  Bryan R Haugen; David S Cooper; Charles H Emerson; Markus Luster; Rui M B Maciel; Rosa P M Biscolla; Ernest L Mazzaferri; Geraldo Medeiros-Neto; Christoph Reiners; Richard J Robbins; Bruce G Robinson; Martin Schlumberger; Shunichi Yamashita; Furio Pacini
Journal:  Thyroid       Date:  2008-07       Impact factor: 6.568

3.  PRR15 Is a Novel Diagnostic and Prognostic Biomarker in Papillary Thyroid Cancer and Modulates the Tumor Microenvironment.

Authors:  Lingli Wang; Xiaoqing Deng; Yi Chen; Yixia Zhao; Zhirong Li
Journal:  J Oncol       Date:  2022-09-15       Impact factor: 4.501

4.  Stimulated Serum Thyroglobulin Levels versus Unstimulated Serum Thyroglobulin in the Follow-up of Patients with Papillary Thyroid Carcinoma.

Authors:  Saumya Sara Sunny; Julie Hephzibah; David Mathew; Joseph Dian Bondu; Nylla Shanthly; Regi Oommen
Journal:  World J Nucl Med       Date:  2018 Jan-Mar
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.